Additionally, MB-2006 treatment leads to a decrease in the production of pro-inflammatory cytokines, such as IL-4, IL-13, TSLP, and TARC, which are regulated by NF-κB, thereby helping to reduce inflammation and alleviate AD symptoms. Here, CCL17 is linked to Alzheimer disease.